Variables | Number of patients (N = 183) | |
---|---|---|
No | % | |
Age, median (range) | 46 (25–71) | |
Histology | ||
Invasive ductal carcinoma | 167 | 91.3 |
Premenopausal/Postmenopausal | 109/74 | 59.6/40.4 |
Regimen of Neoadjuvant Chemotherapy | ||
Concurrent anthracycline + taxane | 128 | 69.9 |
Sequential anthracycline + taxane | 47 | 25.7 |
HER-2 directed agent containing regimen | 10 | 5.5 |
Doxorubicin plus cyclophosphamide | 1 | 0.5 |
Type of Surgery | ||
Breast conserving surgery | 104 | 56.8 |
Mastectomy | 79 | 43.2 |
Initial Clinical Stage | ||
IIA | 3 | 1.6 |
IIB | 27 | 14.8 |
IIIA | 94 | 51.4 |
IIIB | 26 | 14.2 |
IIIC | 33 | 18.0 |
Hormone receptor and HER2 expression status | ||
Hormone receptor (+) | 106 | 57.9 |
HER2 (+) | 58 | 31.7 |
Pathologic Stage | ||
yp0 | 22 | 12.0 |
ypIA | 41 | 22.4 |
ypIIA | 42 | 23.0 |
ypIIB | 22 | 12.0 |
ypIIIA | 38 | 20.8 |
ypIIIB | 2 | 1.1 |
ypIIIC | 16 | 8.7 |
Adjuvant therapy | ||
Radiation therapy | 158 | 86.3 |
Chemotherapy | 62 | 33.9 |
Trastuzumab | 55 | 94.8 % of patients with HER2 positive tumor |
Hormonal therapy | 103 | 97.1 % of patients with HR positive tumor |